Skip to main navigation menu Skip to main content Skip to site footer


Vol 9 No 2 (2024): December

Investigation Study of Cephalexin Capsule Content from Different Drug Companies Available in the Iraqi Pharmaceutical Market

(*) Corresponding Author
December 29, 2023


This study aimed to evaluate the cephalexin content in different capsule formulations from various pharmaceutical companies in the Iraqi market, ensuring medication safety and efficacy. Utilizing computerized High-Performance Liquid Chromatography (HPLC), we analyzed the cephalexin (500 mg) capsules, employing a calibration curve plotted with varying concentrations of external standard cephalexin USP. The purity of cephalexin was further verified through U.V. and I.R. studies. Our quantitative analysis focused on determining the active ingredient's weight based on the area under the peak. The results affirmed that all samples were within the 90%-120% range permitted by the USP 2007 standards, with recoveries approximating 100%, indicating remarkable accuracy and precision. Interestingly, BRULEXIN brand demonstrated the closest recovery to 100%. These findings suggest the effectiveness of HPLC as a rapid, accurate, and sensitive method for pharmaceutical analysis, not only for cephalexin but potentially for other medications as well, highlighting its suitability for routine quality control in the pharmaceutical industry.

Highlights :

  • All cephalexin capsule samples met the USP 2007 standard, indicating consistent quality in the Iraqi pharmaceutical market.
  • High accuracy and precision of HPLC in quantifying active ingredients highlight its potential for broader pharmaceutical applications.
  • BRULEXIN brand showed the closest to 100% recovery, underscoring the variability among different manufacturers.

Keywords : Cephalexin Capsules, HPLC Analysis, Pharmaceutical Quality Control, Iraqi Market, Drug Purity


  1. D. Kasper, A. S. Fauci, and D. Longo, "Harrisons Principles of Internal Medicine," 16th ed., The McGraw-Hill Companies, USA, 2007, pp. 695.
  2. W. Leviston, "Review of Medical Microbiology and Immunology," 9th ed., The McGraw-Hill Companies, USA, 2006, pp. 69.
  3. R. A. Harvey, P. C. Champe, R. D. Howland, and M. J. Mycek, "Lippincott’s Illustrated Reviews: Pharmacology," 3rd ed., Lippincott Williams & Wilkins, USA, 2006, pp. 359.
  4. Y. H. Khang, "Study Of Pure And Conjugated Culture Batch Fermentation Of Cephalosporium Acremonium," M.S. thesis, Dept. Chem. Eng., Texas Tech Univ., Texas, USA, 1986, pp. 4-8.
  5. F. A. AL-Omary, "Monocyclic β-lactams thesis," College of Pharmacy, King Saud Univ., 2000, pp. 2.
  6. E. A. Khan and S. A. Bangash, "Recommendations for Appropriate Use of Antimicrobials at Hospitals in Pakistan (First of two parts)," Dept. of Infectious Disease and Infection Control, 2003.
  7. R. Fongjie, "Analysis of Aminoglycoside Antibiotic by Reversed Phase HPLC," Agilent Tech., Inc., China, 2007.
  8. H. Hahdi, "Asymmetric Approaches to the Tetracycline Antibiotics," 2005, pp. 9-16.
  9. P. Mishra, "Biocoordination and Computational Modeling Ligand with Bi(v)," Int. J. of Chem. Tech. Res., vol. 1, 2009, pp. 401-419.
  10. I. Andersson, A. C. Terwisscha, V. Scheltinga, and K. Valegard, "Towards new β-lactams antibiotics," CMLS, Cell. Mol. Life Sci., vol. 58, 2001, pp. 1897–1906.
  11. J. D. Nguessan et al., “Antibacterial Activity of the Aqueous Extract of Thionningia Sanguinea against Extended-spectrum B-Lactamases producing Escherichia coli and Klebseiella Pneumonia Strains,” Topical J. Pharm. Res., vol. 3, pp. 779-783, 2007.
  12. C. J. Christopher and D. Bratcher, “Cephalosporin: A review,” Amer. Acad. of Pedia. J., vol. 29, 2008.
  13. A. Jalil, I. Niazi, and S. Khan, “Evaluation of Restoration of Sensitivities of Resistant Staphylococcus Aureus isolates by using Cefuroxime and Clavulonic Acid in Combination,” Peshawar J., vol. 2, pp. 20, 2008.
  14. A. Brakhage, “Molecular Regulation of β-lactams Biosynthesis in filamentous,” Micro. & Molec. Biol. Rev. J., vol. 62, pp. 547-585, 1998.
  15. K. Motala, “Penicillin Allergy in Children S,” Allergy Clinic, Division of Paediatric Medicine, University of Cape Town & Red Cross War Memorial Childrens’ Hospital, Cape Town, Sou. Afri. Curr. Aller. & Clin. Immuno. J, vol. 22, pp. 22, 2009.
  16. C. C. Muniz et al., “Penicillin and cephalosporin production, A historical perspective,” J., vol. 49, pp. 88-98, 2007.
  17. T. D. Gootz, “Discovery and Development of new Antimicrobial Agent,” Amer. Soci. of Micr. J., vol. 3, pp. 13-31, 1990.
  18. Authority of Ethiopia, “Drug administration and control,” National Drug Formu. of Ethiop. J., pp. 172-218, 2007.
  19. H. Kalant, D. M. Grant, and J. Mitchell, Principle of Medical Pharmacology, 7th ed., Elsevier, United States of America, pp. 678, 2007.
  20. A. Mohammad, S. Sharma, and S. A. Bhawani, “Chromatographic Separation Studies of Cephalosporins on CTAB Modified Silica Layers,” Int. J. of Chem. Tech. Res., vol. 1, pp. 591-595, 2009.
  21. A. Chaudhury, “In vitro Activity of cefpirome: A new fourth generation cephalosporin,” India. Med. Micro. J., vol. 1, pp. 52-55, 2003.
  22. C. R. Pennington, “Antibiotic: new antibiotics and advances in antibiotic treatment,” Brit. Med. J., vol. 286, pp. 55-60, 1983.
  23. A. Ali, “H2-Antagonist Cephalosporin Interaction,” Thesis, Department of Chemistry, University of Karachi, pp. 7-22, 2003.
  24. D. R. Deanne and D. S. Carson, Infectious Disease in Obstetrics and Gynecology, Medical University of South Carolina, Charleston, 1997.
  25. European Medicines Agency, “Veterinary medicines and Inspection,” 2009.
  26. A. D. Russell and R. H. Fountain, “Aspects of the mechanism of action of some cephalosporins,” Amer. Soc. for Microb. J., vol. 106, pp. 65-69, 1971.
  27. U. Tekur, “Antimicrobial agents: antibacterial drugs,” 2007.
  28. G. Thomas, Medicinal Chemistry, 2nd ed., Wiley, Canada, pp. 239, 2007.
  29. A. D. Deshpande, K. G. B. Baheti, and N. R. Chatterjee, “Degradation of β-lactams antibiotics,” Curr. Sci. J., vol. 87, pp. 26-76, 2004.
  30. I. Anderssons, T. Schettinga, and K. valegard, “Review Towards new β-lactams Antibiotics,” Departments of Molecular Biology, Swedish University of Agricultural Sciences, 2001.
  31. N. Sultan and S. M. Arayne, "Invitro Activity of Cefadroxil, Cephalexin, Cefatrizine and Cefpirome in Presence of Essential and Trace Elements," Pak. J. Pharm. Sci., vol. 20, pp. 305-310, 2007.
  32. A. O. OKesola, "Resistance to Third Generation Cephalosporins and other Antibiotics by Enterobacteriaceae in western Nigeria," Amer. Infec. Dise. J., vol. 5, pp. 17-20, 2009.
  33. M. E. Pichichero, "Prescribing Cephalosporins to penicillin –Allergic patients," University of Rochester, 2005.
  34. S. S. Roach and S. M. Ford, Introductory Clinical Pharmacology, 8th ed., Lippincott Williams & Wilkins, USA, 2008, pp. 93.
  35. J. H. Block, J. M. Beale Jr., Wilson and Gisvold’s Textbook of Organic Medicinal and Pharmaceutical Chemistry, 11th ed., Lippincott Williams & Wilkins, USA, 2004, pp. 325.
  36. D. A. Zarnoff, S. Belkuap, and R. A. Branch, Physicians GenRx The Complete Drug References, 1996, pp. 11-382.
  37. USP/NF, 2004, p. 394.
  38. P. M. Dewick, Essentials of Organic Chemistry, 2nd ed., Wiley, Canada, 2006, pp. 216.
  39. A. C. Moffat, J. V. Jackson, M. S. Moss, and B. Widdop, Clarkes Isolation and Identification of Drugs, 2nd ed., The Pharmaceutical Society of Great Britain, 1986, pp. 438.
  40. A. A. Attama, P. O. Nnamani, and A. N. Agbo, "Development of Alternative Assay Technique for Cephalexin by Charge Transfer Interaction of the Donor: Acceptor Type with Chloranilic Acid," Chin. Pharma. J., vol. 58, pp. 11-18, 2006.
  41. British National Formulary, BNF-55, March 2008, pp. 291-292.
  42. Y. Kazakevich and R. Lobrutto, HPLC for Pharmaceutical Scientists, 11th ed., Wiley, USA, 2007, pp. 3-9.
  43. R. L. Shriner, C. K. F. Hermann, T. C. Morrill, D. Y. Curtin, and R. C. Fuson, The Systematic Identification of Organic Compounds, 8th ed., Wiley & Sons Inc., John, USA, 2004, pp. 109.
  44. D. G. Watson, Pharmaceutical Analysis, 2nd ed., Churchill Livingstone, London, 2000, pp. 195.
  45. J. W. Lehman, "Thin-Layer and Column Chromatography: Identifying an Unknown Analgesic, Determining an Ideal Mobile Phase and Monitoring the Progress of the Mitsunobu Reaction," Ben Zene J., 1999, pp. 618.
  46. S. Ahuja and M. W. Dong, Hand Book of Pharmaceutical Analysis by HPLC, 6th ed., Elsevier, USA, 2005, pp. 20-21.
  47. C. Ho and G.-L. Chen, "Stability–indicating High-Performance Liquid Chromatographic Assay Methods For Drugs in Pharmaceutical Dosage Forms," Food & Drug Ana. J., vol. 4, pp. 271-292, 1996.
  48. S. M. AL. Ghanam, "Spectrophotometric and Atomic Absorption Spectrometric Determination of Cephalexin and Cephradine in Dosage Form," Food and Drug Ana. J., vol. 16, pp. 19-25, 2008.
  49. A. A. Mohammad, "Determination of Cephalexin by Direct (UV-Vis) Spectrophotometer and Indirect (Flame Atomic Absorption) Technique," Iraqi. Pharm. Sci. J., vol. 18, pp. 49, 2009.
  50. British Pharmacopoeia, Medicines and Health Care Products Regulatory Agency, 2008, pp. 418.


Download data is not yet available.